IP Library › Granted Patent US 12,708,629
Granted Patent B2
US 12,708,629 · App. 18/141,805 · Granted Aug 18, 2026

Methods and compositions for reducing parathyroid levels

Inventors: Eric J. Messner (Lake Forest, IL); P. Martin Petkovich (Kingston, CA); Jay A. White (Newmarket, CA); Samir P. Tabash (Whitby, CA); Joel Z. Melnick (Evanston, IL); Charles W Bishop (Miami, FL)
Assignee: EIRGEN PHARMA LTD.
A61K31/593A61K9/4858A61K31/592
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,629
App. No.
18/141,805
Granted
Aug 18, 2026
Kind
B2
Abstract

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.

Claims (21)

1 . A method of treating secondary hyperparathyroidism, comprising orally administering to a human patient suffering from secondary hyperparathyroidism an effective amount of a modified release dosage form comprising 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination thereof, to provide a rise in serum total 25-hydroxyvitamin D of at least 7 ng/ml and no greater than 30 ng/ml within the first 24 hours after said administering and lower the patient's serum intact parathyroid hormone (iPTH) level by at least 10% compared to baseline within 24 hours after said administering.

2 . The method according to claim 1 , wherein the amount of said modified release dosage form administered is effective to provide a rise in serum total 25-hydroxyvitamin D of at least 8 ng/ml and no greater than 16 ng/ml within the first 24 hours after dosing.

3 . The method according to claim 2 , wherein the amount of said modified release dosage form administered is effective to provide a rise in serum total 25-hydroxyvitamin D of at least 10 ng/ml and no greater than 14 ng/ml within the first 24 hours after dosing.

4 . The method of claim 1 , wherein the patient's serum total 25-hydroxyvitamin D is raised to at least 30 ng/ml.

5 . The method of claim 1 , wherein the patient's iPTH level is lowered by at least 15% compared to baseline.

6 . The method of claim 1 , wherein the patient's iPTH level remains lowered for at least 48 hours.

7 . The method of claim 6 , wherein the patient's iPTH level remains lowered for at least 7 days.

8 . The method of claim 1 , wherein said method of treatment further comprises performing said administering step on a frequency of every other day, or less.

9 . The method of claim 8 , wherein said frequency is weekly.

10 . The method of claim 9 , wherein said frequency is monthly.

11 . The method of claim 1 , wherein the bioavailable amount of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination thereof administered is greater than 45 μg.

12 . The method of claim 11 , wherein the bioavailable amount of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination thereof administered is in a range of 70 to 110 μg.

13 . The method of claim 1 , wherein the patient suffers from hyperparathyroidism secondary to chronic kidney disease (CKD).

14 . The method of claim 13 , wherein said CKD is Stage 2, Stage 3, Stage 4, or Stage 5 CKD.

15 . The method of claim 14 , wherein said CKD is Stage 3 or Stage 4.

16 . The method of claim 1 , wherein the amount of said modified release dosage form administered is further effective to provide a rise in serum total 1,25-dihydroxyvitamin D of greater than 3 pg/ml and less than 10 pg/ml within the first 24 hours after dosing.

17 . The method of claim 16 , wherein the rise in serum total 1,25-dihydroxyvitamin D is at least 7 pg/ml and less than 10 pg/ml within the first 48 hours after dosing.

18 . The method of claim 1 , wherein the T max of serum total 25-hydroxyvitamin D following said administering step is at least 4 hours.

19 . The method of claim 18 , wherein the T max of serum total 25-hydroxyvitamin D following said administering step is at least 12 hours.

20 . The method of claim 1 , wherein the patient also suffers from vitamin D insufficiency or deficiency, as defined by serum total 25-hydroxyvitamin D of less than 30 ng/ml.

21 . The method of claim 1 , wherein the modified release dosage form comprises 25-hydroxyvitamin D 3 .

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: OPKO IRELAND GLOBAL HOLDINGS LTD.
To: EIRGEN PHARMA LTD.
Reel/Frame 066635/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: PROVENTIV THERAPEUTICS, LLC
To: OPKO HEALTH, INC.
Reel/Frame 066636/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: CYTOCHROMA INC.
To: CYTOCHROMA CAYMAN ISLANDS LTD.
Reel/Frame 066726/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: PETKOVICH, P. MARTIN; WHITE, JAY A.; TABASH, SAMIR P.; MELNICK, JOEL Z.
To: CYTOCHROMA INC.
Reel/Frame 066635/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: CYTOCHROMA CAYMAN ISLANDS LTD.
To: OPKO IP HOLDINGS II, INC.
Reel/Frame 066635/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: OPKO HEALTH, INC.
To: OPKO RENAL, LLC
Reel/Frame 066636/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: OPKO IP HOLDINGS II, INC.
To: OPKO IRELAND GLOBAL HOLDINGS, LTD.
Reel/Frame 066635/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: MESSNER, ERIC J.; BISHOP, CHARLES W.
To: PROVENTIV THERAPEUTICS, LLC
Reel/Frame 066635/0964 →
Continuity (4)
Continuation 13638845 · Mar 29, 2011
Provisional Application 61405196 · Oct 20, 2010
Provisional Application 61318741 · Mar 29, 2010
Related Publication 20230346804A1 · Nov 2, 2023
References Cited (400)
US 3565924A · Luca et al. · 1971 [cited by applicant]
US 3833622A · Babcock et al. · 1974 [cited by applicant]
US 3880894A · De et al. · 1975 [cited by applicant]
US 3974272A · Polli et al. · 1976 [cited by applicant]
US 4004003A · Babcock et al. · 1977 [cited by applicant]
US 4230701A · Holick et al. · 1980 [cited by applicant]
US 4335120A · Holick et al. · 1982 [cited by applicant]
US 4442093A · Maeda et al. · 1984 [cited by applicant]
US 4448721A · Deluca et al. · 1984 [cited by applicant]
US 4555364A · Deluca et al. · 1985 [cited by applicant]
US 4668517A · Weber et al. · 1987 [cited by applicant]
US 4684524A · Eckenhoff et al. · 1987 [cited by applicant]
US 4695591A · Hanna et al. · 1987 [cited by applicant]
US 4721613A · Urquhart et al. · 1988 [cited by applicant]
US 4729895A · Makino et al. · 1988 [cited by applicant]
US 4755544A · Makino et al. · 1988 [cited by applicant]
US 4892821A · Omura et al. · 1990 [cited by applicant]
US 4997824A · Popovtzer et al. · 1991 [cited by applicant]
US 5026559A · Eichel et al. · 1991 [cited by applicant]
US 5160742A · Mazer et al. · 1992 [cited by applicant]
US 5167965A · Schulz · 1992 [cited by applicant]
US 5328903A · Ishii et al. · 1994 [cited by applicant]
US 5342626A · Winston et al. · 1994 [cited by applicant]
US 5354743A · Thys-Jacobs · 1994 [cited by applicant]
US 5403831A · Deluca et al. · 1995 [cited by applicant]
US 5431917A · Yamamoto et al. · 1995 [cited by applicant]
US 5472712A · Oshlack et al. · 1995 [cited by applicant]
US 5487900A · Itoh et al. · 1996 [cited by applicant]
US 5529991A · Knutson et al. · 1996 [cited by applicant]
US 5593690A · Akiyama et al. · 1997 [cited by applicant]
US 5602116A · Knutson et al. · 1997 [cited by applicant]
US 5614513A · Knutson et al. · 1997 [cited by applicant]
US 5622941A · Knutson et al. · 1997 [cited by applicant]
US 5693615A · Stone · 1997 [cited by applicant]
US 5707980A · Knutson et al. · 1998 [cited by applicant]
US 5756123A · Yamamoto et al. · 1998 [cited by applicant]
US 5783215A · Arwidsson et al. · 1998 [cited by applicant]
US 5795882A · Bishop et al. · 1998 [cited by applicant]
US 5861386A · Knutson et al. · 1999 [cited by applicant]
US 5869473A · Knutson et al. · 1999 [cited by applicant]
US 5872113A · Nestor et al. · 1999 [cited by applicant]
US 5888994A · Hennessy et al. · 1999 [cited by applicant]
US 5919986A · Barbier et al. · 1999 [cited by applicant]
US 5939408A · Batcho et al. · 1999 [cited by applicant]
US 5958451A · Chen · 1999 [cited by applicant]
US 5976784A · Deluca et al. · 1999 [cited by applicant]
US 6001884A · Nemeth et al. · 1999 [cited by applicant]
US 6011068A · Nemeth et al. · 2000 [cited by applicant]
US 6031003A · Nemeth et al. · 2000 [cited by applicant]
US 6034075A · Thys-Jacobs · 2000 [cited by applicant]
US 6051567A · Abrahamson et al. · 2000 [cited by applicant]
US 6096876A · St-Arnaud et al. · 2000 [cited by applicant]
US 6121469A · Norman et al. · 2000 [cited by applicant]
US 6133250A · Knutson et al. · 2000 [cited by applicant]
US 6139875A · Adams et al. · 2000 [cited by applicant]
US 6147064A · Knutson et al. · 2000 [cited by applicant]
US 6150346A · Knutson et al. · 2000 [cited by applicant]
US 6190591B1 · Van Lengerich · 2001 [cited by applicant]
US 6190695B1 · Hoshino et al. · 2001 [cited by applicant]
US 6211244B1 · Van et al. · 2001 [cited by applicant]
US 6214376B1 · Gennadios · 2001 [cited by applicant]
US 6228849B1 · Thys-Jacobs · 2001 [cited by applicant]
US 6242434B1 · Bishop et al. · 2001 [cited by applicant]
US 6265392B1 · Abrahamson et al. · 2001 [cited by applicant]
US 6274169B1 · Abrahamson et al. · 2001 [cited by applicant]
US 6288849B1 · Teramoto · 2001 [cited by applicant]
US 6313146B1 · Van et al. · 2001 [cited by applicant]
US 6340473B1 · Tanner et al. · 2002 [cited by applicant]
US 6342249B1 · Wong et al. · 2002 [cited by applicant]
US 6375981B1 · Gilleland et al. · 2002 [cited by applicant]
US 6376479B1 · Knutson et al. · 2002 [cited by applicant]
US 6380408B1 · Posner et al. · 2002 [cited by applicant]
US 6413463B1 · Yamamoto et al. · 2002 [cited by applicant]
US 6432936B1 · Deluca et al. · 2002 [cited by applicant]
US 6491950B1 · Gutierrez-Rocca et al. · 2002 [cited by applicant]
US 6503893B2 · Bishop et al. · 2003 [cited by applicant]
US 6521608B1 · Henner et al. · 2003 [cited by applicant]
US 6524788B1 · Cantor · 2003 [cited by applicant]
US 6569463B2 · Patel et al. · 2003 [cited by applicant]
US 6572888B2 · Byrd · 2003 [cited by applicant]
US 6582727B2 · Tanner et al. · 2003 [cited by applicant]
US 6596314B2 · Wong et al. · 2003 [cited by applicant]
US 6627622B2 · Deluca et al. · 2003 [cited by applicant]
US 6645527B2 · Oshlack et al. · 2003 [cited by applicant]
US 6770295B1 · Kreilgaard et al. · 2004 [cited by applicant]
US 6887493B2 · Shefer et al. · 2005 [cited by applicant]
US 6893658B1 · Iida et al. · 2005 [cited by applicant]
US 6903083B2 · Knutson et al. · 2005 [cited by applicant]
US 6911217B1 · Gren et al. · 2005 [cited by applicant]
US 6923988B2 · Patel et al. · 2005 [cited by applicant]
US 6929803B2 · Wong et al. · 2005 [cited by applicant]
US 6949256B2 · Fonkwe et al. · 2005 [cited by applicant]
US 6982258B2 · Posner et al. · 2006 [cited by applicant]
US RE39079E · Tanner et al. · 2006 [cited by applicant]
US 7033996B2 · Christakos · 2006 [cited by applicant]
US 7056655B2 · Cantor · 2006 [cited by applicant]
US 7101865B2 · Posner et al. · 2006 [cited by applicant]
US 7122530B2 · Bishop et al. · 2006 [cited by applicant]
US 7166585B2 · Posner et al. · 2007 [cited by applicant]
US 7189843B2 · Tsai et al. · 2007 [cited by applicant]
US 7226932B2 · Gokhale et al. · 2007 [cited by applicant]
US 7255921B2 · Kamaguchi et al. · 2007 [cited by applicant]
US 7422758B2 · Block et al. · 2008 [cited by applicant]
US 7528122B2 · Deluca et al. · 2009 [cited by applicant]
US 7632518B2 · Tritsch et al. · 2009 [cited by applicant]
US 7648826B1 · Albertson et al. · 2010 [cited by applicant]
US 7807194B2 · Modliszewski et al. · 2010 [cited by applicant]
US 7816341B2 · Sewall et al. · 2010 [cited by applicant]
US 7829595B2 · Lawrence et al. · 2010 [cited by applicant]
US 7846475B2 · Shiraishi et al. · 2010 [cited by applicant]
US 7973024B2 · Posner et al. · 2011 [cited by applicant]
US 8088410B2 · Tritsch et al. · 2012 [cited by applicant]
US 8101203B2 · Cao · 2012 [cited by applicant]
US 8101204B2 · Cao · 2012 [cited by applicant]
US 8142811B2 · Oshlack et al. · 2012 [cited by applicant]
US 8207149B2 · Tabash et al. · 2012 [cited by applicant]
US 8231896B2 · Tanner et al. · 2012 [cited by applicant]
US 8268352B2 · Vaya et al. · 2012 [cited by applicant]
US 8293270B2 · Sukuru · 2012 [cited by applicant]
US 8329677B2 · Bishop et al. · 2012 [cited by applicant]
US 8361488B2 · Bishop et al. · 2013 [cited by applicant]
US 8377470B2 · Tanner et al. · 2013 [cited by applicant]
US 8426391B2 · Bishop et al. · 2013 [cited by applicant]
US 8592401B2 · Petkovich et al. · 2013 [cited by applicant]
US 8759328B2 · Deluca et al. · 2014 [cited by applicant]
US 8778373B2 · Bishop et al. · 2014 [cited by applicant]
US 8906410B2 · Bishop et al. · 2014 [cited by applicant]
US 8962239B2 · Petkovich et al. · 2015 [cited by applicant]
US 8992971B2 · Yang · 2015 [cited by applicant]
US 9017720B2 · Andersen et al. · 2015 [cited by applicant]
US 9125823B2 · Selva et al. · 2015 [cited by applicant]
US 9402855B2 · Bishop et al. · 2016 [cited by applicant]
US 9408858B2 · Bishop et al. · 2016 [cited by applicant]
US 9498486B1 · Bishop et al. · 2016 [cited by applicant]
US 9500661B2 · Petkovich et al. · 2016 [cited by applicant]
US 9913852B2 · Bishop et al. · 2018 [cited by applicant]
US 9918940B2 · Bishop et al. · 2018 [cited by applicant]
US 10220047B2 · Petkovich et al. · 2019 [cited by applicant]
US 20010028896A1 · Byrd · 2001 [cited by applicant]
US 20010036472A1 · Wong et al. · 2001 [cited by applicant]
US 20020018810A1 · Oshlack et al. · 2002 [cited by applicant]
US 20020031798A1 · Anazawa et al. · 2002 [cited by applicant]
US 20020044968A1 · Van Lengerich · 2002 [cited by applicant]
US 20020081331A1 · Tanner et al. · 2002 [cited by applicant]
US 20020128240A1 · Mazess · 2002 [cited by applicant]
US 20020155154A1 · Wong et al. · 2002 [cited by applicant]
US 20020183288A1 · Mazess et al. · 2002 [cited by applicant]
US 20030059471A1 · Compton et al. · 2003 [cited by applicant]
US 20030083360A1 · Crotts et al. · 2003 [cited by applicant]
US 20030129194A1 · Mazess et al. · 2003 [cited by applicant]
US 20030138482A1 · Fonkwe et al. · 2003 [cited by applicant]
US 20030152629A1 · Shefer et al. · 2003 [cited by applicant]
US 20030157560A1 · Cantor · 2003 [cited by applicant]
US 20030191093A1 · Chen et al. · 2003 [cited by applicant]
US 20030195171A1 · Daifotis et al. · 2003 [cited by applicant]
US 20040043971A1 · Mazess et al. · 2004 [cited by applicant]
US 20040092534A1 · Yam et al. · 2004 [cited by applicant]
US 20040101554A1 · Kirschner et al. · 2004 [cited by applicant]
US 20040132695A1 · Posner et al. · 2004 [cited by applicant]
US 20040197407A1 · Subramanian et al. · 2004 [cited by applicant]
US 20040224930A1 · Posner et al. · 2004 [cited by applicant]
US 20040258749A1 · Guldner et al. · 2004 [cited by applicant]
US 20050014211A1 · Armbruster et al. · 2005 [cited by applicant]
US 20050019374A1 · Modliszewski et al. · 2005 [cited by applicant]
US 20050037064A1 · Basquin et al. · 2005 [cited by applicant]
US 20050069579A1 · Kamaguchi et al. · 2005 [cited by applicant]
US 20050101576A1 · Whitehouse et al. · 2005 [cited by applicant]
US 20050106233A1 · Andersen et al. · 2005 [cited by applicant]
US 20050124591A1 · Tian et al. · 2005 [cited by applicant]
US 20050143358A1 · Deluca et al. · 2005 [cited by applicant]
US 20050147669A1 · Lawrence et al. · 2005 [cited by applicant]
US 20050148557A1 · Tian et al. · 2005 [cited by applicant]
US 20050148558A1 · Knutson et al. · 2005 [cited by applicant]
US 20050186268A1 · Hoshi et al. · 2005 [cited by applicant]
US 20050208055A1 · Chuang et al. · 2005 [cited by applicant]
US 20050287213A1 · Wong et al. · 2005 [cited by applicant]
US 20060009425A1 · Delgado-Herrera et al. · 2006 [cited by applicant]
US 20060019933A1 · Boardman et al. · 2006 [cited by applicant]
US 20060029660A1 · Fonkwe et al. · 2006 [cited by applicant]
US 20060034937A1 · Patel · 2006 [cited by applicant]
US 20060057201A1 · Bonney et al. · 2006 [cited by applicant]
US 20060193877A1 · Tengler et al. · 2006 [cited by applicant]
US 20060210610A1 · Davidson et al. · 2006 [cited by applicant]
US 20060223119A1 · Cantor · 2006 [cited by applicant]
US 20060228808A1 · Clarke et al. · 2006 [cited by applicant]
US 20060257481A1 · Gurney et al. · 2006 [cited by applicant]
US 20070026067A1 · Yam et al. · 2007 [cited by applicant]
US 20070027120A1 · Whitehouse et al. · 2007 [cited by applicant]
US 20070032461A1 · Adorini et al. · 2007 [cited by applicant]
US 20070122477A1 · Bishop et al. · 2007 [cited by applicant]
US 20070155664A1 · Ranklove et al. · 2007 [cited by applicant]
US 20070190146A1 · Roger et al. · 2007 [cited by applicant]
US 20070207488A1 · Trump et al. · 2007 [cited by applicant]
US 20080109983A1 · Davis · 2008 [cited by applicant]
US 20080134937A1 · Yang · 2008 [cited by applicant]
US 20080199534A1 · Goldberg et al. · 2008 [cited by applicant]
US 20080317764A1 · Huber et al. · 2008 [cited by applicant]
US 20090004284A1 · Cheng et al. · 2009 [cited by applicant]
US 20090069389A1 · Choi et al. · 2009 [cited by applicant]
US 20090137536A1 · Mazess et al. · 2009 [cited by applicant]
US 20090155355A1 · Heuer et al. · 2009 [cited by applicant]
US 20090176748A1 · Tabash et al. · 2009 [cited by applicant]
US 20090209501A1 · Bishop et al. · 2009 [cited by applicant]
US 20090262685A1 · Schuringa et al. · 2009 [cited by applicant]
US 20090311316A1 · Bishop et al. · 2009 [cited by applicant]
US 20100120728A1 · Petkovich et al. · 2010 [cited by applicant]
US 20100144684A1 · Bishop · 2010 [cited by applicant]
US 20100204189A1 · Petkovich et al. · 2010 [cited by applicant]
US 20100227889A1 · Gerspacher et al. · 2010 [cited by applicant]
US 20100291191A1 · Shoichet et al. · 2010 [cited by applicant]
US 20100291197A1 · Schwab · 2010 [cited by applicant]
US 20110039809A1 · Buck et al. · 2011 [cited by applicant]
US 20110039810A1 · Buck et al. · 2011 [cited by applicant]
US 20110039811A1 · Buck et al. · 2011 [cited by applicant]
US 20110105444A1 · Deluca et al. · 2011 [cited by applicant]
US 20110118218A1 · Buck et al. · 2011 [cited by applicant]
US 20110130370A1 · Briault et al. · 2011 [cited by applicant]
US 20110171298A1 · Cao · 2011 [cited by applicant]
US 20110182986A1 · Speirs et al. · 2011 [cited by applicant]
US 20110256230A1 · Haeusler et al. · 2011 [cited by applicant]
US 20110300210A1 · Swanson et al. · 2011 [cited by applicant]
US 20110318321A1 · Selva et al. · 2011 [cited by applicant]
US 20110319503A1 · Muller et al. · 2011 [cited by applicant]
US 20120015916A1 · Tabash et al. · 2012 [cited by applicant]
US 20120135103A1 · Walsh et al. · 2012 [cited by applicant]
US 20130085121A1 · Wang et al. · 2013 [cited by applicant]
US 20130137663A1 · Messner et al. · 2013 [cited by applicant]
US 20130178451A1 · Bishop et al. · 2013 [cited by applicant]
US 20130189522A1 · Fujii et al. · 2013 [cited by applicant]
US 20130216618A1 · Muller et al. · 2013 [cited by applicant]
US 20130302309A1 · Yang · 2013 [cited by applicant]
US 20140088202A1 · Cade et al. · 2014 [cited by applicant]
US 20140248400A1 · Phonchareon et al. · 2014 [cited by applicant]
US 20140274977A1 · Bishop et al. · 2014 [cited by applicant]
US 20140349979A1 · White et al. · 2014 [cited by applicant]
US 20140357603A1 · Bishop et al. · 2014 [cited by applicant]
US 20150079165A1 · Bishop et al. · 2015 [cited by applicant]
US 20150119472A1 · Shuai et al. · 2015 [cited by applicant]
US 20150119473A1 · Shuai et al. · 2015 [cited by applicant]
US 20170119677A1 · Bishop et al. · 2017 [cited by applicant]
US 20180021354A1 · Petkovich et al. · 2018 [cited by applicant]
CA 2241205A1 · 1997 [cited by applicant]
CN 101668517A · 2010 [cited by applicant]
DE 20321698U1 · 2008 [cited by applicant]
EP 0227836A1 · 1987 [cited by applicant]
EP 0413828A1 · 1991 [cited by applicant]
EP 0508756A1 · 1992 [cited by applicant]
EP 0387808B1 · 1993 [cited by applicant]
EP 0629405A1 · 1994 [cited by applicant]
EP 1080055A2 · 2001 [cited by applicant]
EP 1208843A1 · 2002 [cited by applicant]
EP 1165061B1 · 2005 [cited by applicant]
EP 1980255A1 · 2008 [cited by applicant]
EP 2148661B1 · 2012 [cited by applicant]
EP 2591354A1 · 2013 [cited by applicant]
EP 2037936B1 · 2014 [cited by applicant]
JP 55139320 · 1980 [cited by applicant]
JP 57188520A · 1982 [cited by applicant]
JP 58032823 · 1983 [cited by applicant]
JP 58206524A · 1983 [cited by applicant]
JP 64031722A · 1989 [cited by applicant]
JP 02229115A · 1990 [cited by applicant]
JP 04198129A · 1992 [cited by applicant]
JP 04208225A · 1992 [cited by applicant]
JP 04288016A · 1992 [cited by applicant]
JP 07242550A · 1995 [cited by applicant]
JP 08092098A · 1996 [cited by applicant]
JP 10158171A · 1998 [cited by applicant]
JP 11158074A · 1999 [cited by applicant]
JP 2001512418A · 2001 [cited by applicant]
JP 2002302447A · 2002 [cited by applicant]
JP 2004175750A · 2004 [cited by applicant]
JP 2004531548A · 2004 [cited by applicant]
JP 2005505589A · 2005 [cited by applicant]
JP 2005513419A · 2005 [cited by applicant]
JP 2005528383A · 2005 [cited by applicant]
JP 2005531532A · 2005 [cited by applicant]
JP 2005535682A · 2005 [cited by applicant]
JP 2005538189A · 2005 [cited by applicant]
JP 2006517593A · 2006 [cited by applicant]
JP 2006523221A · 2006 [cited by applicant]
JP 2007525472A · 2007 [cited by applicant]
JP 2010506520A · 2010 [cited by applicant]
JP 2010525079A · 2010 [cited by applicant]
JP 2011512343A · 2011 [cited by applicant]
JP 2012515738A · 2012 [cited by applicant]
KR 1020120005228A · 2012 [cited by applicant]
WO 9112807A1 · 1991 [cited by applicant]
WO 9116899A1 · 1991 [cited by applicant]
WO 9209271A1 · 1992 [cited by applicant]
WO 9400128A1 · 1994 [cited by applicant]
WO 9600074A1 · 1996 [cited by applicant]
WO 9601621A1 · 1996 [cited by applicant]
WO 9631215A1 · 1996 [cited by applicant]
WO 9711053A1 · 1997 [cited by applicant]
WO 9818610A1 · 1998 [cited by applicant]
WO 9829105A2 · 1998 [cited by applicant]
WO 9911272A1 · 1999 [cited by applicant]
WO 9949027A1 · 1999 [cited by applicant]
WO 9961398A2 · 1999 [cited by applicant]
WO 0021504A1 · 2000 [cited by applicant]
WO 0035419A2 · 2000 [cited by applicant]
WO 0060109A1 · 2000 [cited by applicant]
WO 0061123A2 · 2000 [cited by applicant]
WO 0137808A1 · 2001 [cited by applicant]
WO 0172286A1 · 2001 [cited by applicant]
WO 0292056A1 · 2002 [cited by applicant]
WO 0309572A1 · 2003 [cited by applicant]
WO 0330869A1 · 2003 [cited by applicant]
WO 0339521A1 · 2003 [cited by applicant]
WO 0339572A1 · 2003 [cited by applicant]
WO 0345381 · 2003 [cited by applicant]
WO 0347595A1 · 2003 [cited by applicant]
WO 0386267A2 · 2003 [cited by applicant]
WO 0386415A1 · 2003 [cited by applicant]
WO 0388976A1 · 2003 [cited by applicant]
WO 0393459 · 2003 [cited by applicant]
WO 2003106411A1 · 2003 [cited by applicant]
WO 2004010981A1 · 2004 [cited by applicant]
WO 2004028515A1 · 2004 [cited by applicant]
WO 2004054968A2 · 2004 [cited by applicant]
WO 2004058235A2 · 2004 [cited by applicant]
WO 2004071497A1 · 2004 [cited by applicant]
WO 2004080467A2 · 2004 [cited by applicant]
WO 2004098617A2 · 2004 [cited by applicant]
WO 2004101554A1 · 2004 [cited by applicant]
WO 2004110381A2 · 2004 [cited by applicant]
WO 2004110391A2 · 2004 [cited by applicant]
WO 2005000268A2 · 2005 [cited by applicant]
WO 2005003358A1 · 2005 [cited by applicant]
WO 2005011652A3 · 2005 [cited by applicant]
WO 2005123120A1 · 2005 [cited by applicant]
WO 2006052452A1 · 2006 [cited by applicant]
WO 2006059180A2 · 2006 [cited by applicant]
WO 2006113505A2 · 2006 [cited by applicant]
WO 2007039193A1 · 2007 [cited by applicant]
WO 2007039569A2 · 2007 [cited by applicant]
WO 2007047327A2 · 2007 [cited by applicant]
WO 2007050724A2 · 2007 [cited by applicant]
WO 2007050975A2 · 2007 [cited by applicant]
WO 2007053608A2 · 2007 [cited by applicant]
WO 2007068287A1 · 2007 [cited by applicant]
WO 2007092221A2 · 2007 [cited by applicant]
WO 2007092755A2 · 2007 [cited by applicant]
WO 2007146004A1 · 2007 [cited by applicant]
WO 2008008608A3 · 2008 [cited by applicant]
WO 2008043449A1 · 2008 [cited by applicant]
WO 2008097646A1 · 2008 [cited by applicant]
WO 2008116113A1 · 2008 [cited by applicant]
WO 2008116133A1 · 2008 [cited by applicant]
WO 2008134512A1 · 2008 [cited by applicant]
WO 2008134518A2 · 2008 [cited by applicant]
WO 2008134523A1 · 2008 [cited by applicant]
WO 2009047644A2 · 2009 [cited by applicant]
WO 2009101132A1 · 2009 [cited by applicant]
WO 2009101135A1 · 2009 [cited by applicant]
WO 2009101137A1 · 2009 [cited by applicant]
WO 2009124210A1 · 2009 [cited by applicant]
WO 2010011906A1 · 2010 [cited by applicant]
WO 2010034342A1 · 2010 [cited by applicant]
WO 2011031621A2 · 2011 [cited by applicant]
WO 2011063952A1 · 2011 [cited by applicant]
WO 2011095388A1 · 2011 [cited by applicant]
WO 2011123476A1 · 2011 [cited by applicant]
WO 2012006475A1 · 2012 [cited by applicant]
WO 2012018329A1 · 2012 [cited by applicant]
WO 2012076429A1 · 2012 [cited by applicant]
WO 2012091569A1 · 2012 [cited by applicant]
WO 2012117236A1 · 2012 [cited by applicant]
WO 2012145491A2 · 2012 [cited by applicant]
WO 2014029953A1 · 2014 [cited by applicant]
WO 2014143941A1 · 2014 [cited by applicant]
WO 2014193255A1 · 2014 [cited by applicant]
WO 2014202754A1 · 2014 [cited by applicant]
WO 2016020508A2 · 2016 [cited by applicant]
Chandra et al., “Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study,” Endocr.Pract., 14: 10-17 (2008). [cited by applicant]
Charnow, Jody A., Novel Formulation Corrects Vitamin D, Lowers iPTH, available online at <https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2012-%20spring-meeti… [cited by applicant]
Chen et al., Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials, Oncol. Res. Treat., 39(7-9):453-9 (2016). [cited by applicant]
Chonchol et al., 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey, Kidney Int., 71(2):134-9 (2007). [cited by applicant]
Claris-Appiani et al., “Phosphate-Induced PTH Stimulation and Calcitriol Treatment in Children with Early Chronic Renal Insufficiency,” J. Bone Miner. Met., 12:S91-S97 (1994). [cited by applicant]
Coburn et al., “Doxercalciferol Safely Suppresses PTH Levels in Patients with Secondary Hyperparathyroidism Associated with Chronic Kidney Disease Stages 3 and 4,” Am. J. Kidney Dis., 43(5):877-890 (2004). [cited by applicant]
Coburn, “An Update on Vitamin D as Related to Nephrology Practice: 2003,” Kidney International, vol. 64, Supplement 87, pp. S125-S130 (2003). [cited by applicant]
Coburn, et al., “Use of Active Vitamin D Sterols in Patients with Chronic Kidney Disease, Stages 3 and 5,” Kidney International, vol. 63, Supplement 85, pp. S49-S53 (2003). [cited by applicant]
Coen et al., “1,25(OH)2D3 and 25-OHD3 in the Treatment of Renal Osteodystrophy: Comparison of Combined Versus 1,25(OH)2D3 Administration Alone,” Miner. Electrolyte Metab., 9:19-27 (1983). [cited by applicant]
Coen et al., “25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients,” Int J Artificial Organs, 2(6): 278-281 (1979). [cited by applicant]
Cohen-Solal et al., “Non-Aluminic Adynamic Bone Disease in Non-Dialyzed Uremic Patients: A New Type of Osteopathy Due to Overtreatment?” Bone, 13:1-5 (1992). [cited by applicant]
Collet et al. “Modified-Release Peroral Dosage Forms,” Aulton (ed.), Pharmaceutics: The Science of Dosage Forms, Churchill Livingston, London, pp. 289-305 (2002). [cited by applicant]
Colodro et al., “Effect of 25-Hydroxy-Vitamin D3 on Intestinal Absorption of Calcium in Normal Man and Patients With Renal Failure,” Metabolism, 27(6):745-753 (1978). [cited by applicant]
Coyne et al., “Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD,” American Journal of Kidney Diseases, 47(2):263-276 (2006). [cited by applicant]
Daisley-Kydd et al., “Calcitriol in the Management of Secondary Hyperparathyroidism of Renal Failure,” Pharmacotherapy., 16:619-630 (1996). [cited by applicant]
Database WPI Week 199546 Thomson Scientific, London, GB; An 1995-355178 XP002680886. [cited by applicant]
Davies, M. et al. “The Absorption and Metabolism of Vitamin D3 from Parenteral Injection Sites”, Proceedings of the Workshop on Vitamin D, 4th, Vitam. D: Basic Res. Its Clin. Appl. (1979), abstract. [cited by applicant]
DB-Pharma, “Dedrogyl 15 Mg/10ML Calcifediol Oral Drops, Solution,” Marketing Authorization No. 317 863.2 (2000). [cited by applicant]
DeLuca, “Treatment of renal osteodystrophy with 25-hydroxycholecalciferol,” Arch Intern Med, 126(5):896-899 (1970). [cited by applicant]
Deroisy et al., “Comparison of the Short-Term Effects of Three Oral Calcium-Vitamin D Formulations and Placebo on Calcium Metabolism,” Curr. Ther. Res., 59:370-378 (1998). [cited by applicant]
DeVille et al., “Effect of Ergocalciferol Supplementation on Serum Parathyroid Hormone and Serum 25-Hydroxyvitamin D in Chronic Kidney Disease,” Nephrology, 11:555-559 (2006). [cited by applicant]
Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, Natio… [cited by applicant]
Dietary Supplement Fact Sheet: Vitamin D, National Institutes of Health, Office of Dietary Supplements (last update: Aug. 5, 2005), retrieved from <URL: http:ods.od.nih.gov/factsheets/vitamind.asp> on Aug. 31, 2007. [cited by applicant]
Disease and Vitamin D, University of California Riverside, retrieved from Internet, <URL: <http://vitamind.ucr.edu/disease.html>> (last update: May 19, 1999). [cited by applicant]
Disintegration, chapter 701; Dissolution, chapter 711; Distilling Range, chapter 721; Drug Release, chapter 724; Electrophoresis, chapter 726; pp. 276-292, in: U.S. Pharmacopeia vol. 30. 2007. [cited by applicant]